State House News Service

Search:
 

Applied BioMath, LLC Announces Collaboration with Syntimmune for Pharmacokinetic and Pharmacodynamic Modeling in Clinical Program for Autoimmune Diseases

 

LINCOLN, Mass., Dec. 4, 2017 /PRNewswire/ -- Applied BioMath® (www.appliedbiomath.com), the industry leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune's ongoing clinical trials.  Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune's lead drug candidate, SYNT001. The goal is to create a semi-mechanistic PK/PD model to support further advancement of Syntimmune's clinical trials of SYNT001 in a broad variety of IgG-mediated autoimmune diseases, including ongoing trials in Warm Autoimmune Hemolytic Anemia, Pemphigus, and other clinical indications.

"Our collaboration with Applied BioMath will allow us to gain additional validation of SYNT001's differentiated properties, particularly in regard to the dose level, dosing frequency, and planned subcutaneous administration of our promising lead compound.  We anticipate this collaboration will allow us to best optimize FcRn inhibition in the context of therapeutic induction and maintenance, enabled by our deep understanding of the underlying biology," said David de Graaf, PhD, CEO of Syntimmune.  "Applied BioMath has a stellar track record in helping customers with similar objectives, and we look forward to leveraging their capabilities for our program."

Applied BioMath's MADI approach involves rigorous fit-for-purpose model development and optimization techniques to estimate model parameters and variability using proprietary algorithms and software.  Top pharmaceutical and biotechnology companies leverage Applied BioMath's MADI approach to accelerate their candidates to market and to de-risk their research and development (R&D) from early research through to clinical trials.  "We look forward to supporting Syntimmune as they progress further into the clinic," said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath.  "This is a critical stage in R&D where strategic questions benefit greatly from the support of MADI."

About Applied BioMath

Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.  Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.  The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic.   For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com

View original content with multimedia:http://www.prnewswire.com/news-releases/applied-biomath-llc-announces-collaboration-with-syntimmune-for-pharmacokinetic-and-pharmacodynamic-modeling-in-clinical-program-for-autoimmune-diseases-300565995.html

SOURCE Applied BioMath, LLC

Back to top

 

© Copyright 1997-2010 State House News Service - Proud to be an Affiliated Company! | Privacy Policy  | Contact Us |
Room 458 - State House - Boston, MA 02133 | Newsroom Phone: (617) 722-2439 | Newsroom Fax: (617) 720-0341